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Letters to the Editorbody radiation. We are grateful for
the opportunity to discuss these
important issues with you and
look forward to further advances in
the postoperative surveillance and
treatment of lung cancer.
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To the Editor:
We read with interest the article by
Kennedy and colleagues,1 ‘‘Does the
Society of Thoracic Surgeons Risk
Score Accurately Predict Operative
Mortality for Patients With Pulmo-
nary Hypertension?’’ We concur with
Kennedy and colleagues1 that the
current Society of Thoracic Surgeons
system2 poorly models patients with
elevated pulmonary arterial pressure
(PAP) or associated right heart
dysfunction. In our experience and
that of others, patients undergoing car-
diac surgery with PAP hypertension
have worse outcomes than patients
without PAP elevation. An important
question is why is PAP hypertension
an important prognostic marker? To
complement the work by Kennedy
Kennedy and colleagues,1 we would
like to emphasize that although1716 The Journal of Thoracic andelevated PAP is a good marker for
increased morbidity and mortality,
the potential underlying reason for
worse outcomes in these patients is
right heart dysfunction.
For better independent quantifica-
tion of right heart function, we have
begun implementing cardiac magnetic
resonance imaging (cMRI) on a
routine basis for patients deemed to
be at increased risk for right heart
dysfunction arising from elevated
PAP. Use of cMRI allows accurate
interpretation of right ventricular
ejection fraction as well as chamber
volumes or right ventricular end-
diastolic and end-systolic volumes,
which serve as the criterion standard
for establishment of right heart func-
tion in patients with elevated PAP.3
We perform cMRI selectively during
our preoperative workup in patients
with suspected elevated PAP and in
those deemed to be at risk for possible
right heart dysfunction, such as pa-
tients with valvular heart disease and
those with ischemic cardiomy-
opathy.4-6 Patients who are not found
to have any associated right heart
dysfunction are then reevaluated
to establish whether there are
interventions available for medical
optimization, because increased PAP
is often due to other reversible
cardiac causes or noncardiogenic
causes in this subset (sleep apnea,
volume overload, interstitial lung
disease, etc).4 Those who demonstrate
severe right heart dysfunction are also
reevaluated for medical optimization,
as well as for appropriateness of
surgical intervention, especially in
patients with apparent advanced
biventricular disease. Within our
population, this method has allowed
us to improve preoperative risk
stratification and our ability to
select appropriate surgical candidates,
improving our outcomes.5,6
We believe that cMRI should be
used in patients with elevated PAP
(mean PAP >35 mm Hg) to help
define right ventricular function and
better select patients for cardiacCardiovascular Surgery c May 2014surgical procedures. Consideration
should be also given to adding right
heart function to existing risk models
to accurately risk stratify this
population.
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We appreciate the comments by Tra-
chiotis and colleagues on the impor-
tance of right ventricular (RV)
function in perioperative morbidity
and mortality. We agree that a compre-
hensive assessment of RV function
